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ABSTRACT (word count = 200/200) 
Background: Prostate cancer is a common cancer worldwide with no established modifiable 
lifestyle factors to guide prevention. The associations between polyunsaturated fatty acids 
(PUFAs) and prostate cancer risk have been inconsistent. Using Mendelian randomization, we 
evaluated associations between PUFAs and prostate cancer risk. 
Methods: We used individual-level data from a consortium of 22,721 cases and 23,034 controls 
of European ancestry. Externally-weighted PUFA-specific polygenic risk scores (wPRSs), with 
explanatory variation ranging from 0.65-33.07%, were constructed and used to evaluate 
associations with prostate cancer risk per one standard deviation (SD) increase genetically-
predicted plasma PUFA levels using multivariable-adjusted unconditional logistic regression.  
Results: No overall association was observed between the genetically-predicted PUFAs 
evaluated in this study and prostate cancer risk. However, risk reductions were observed for 
short-chain PUFAs, linoleic (ORLA=0.95, 95%CI=0.92,0.98) and α-linolenic acids (ORALA=0.96, 
95%CI=0.93,0.98), among men <62 years; whereas increased risk was found among men ≥62 
years for LA (ORLA=1.04, 95%CI=1.01,1.07). For long-chain PUFAs (i.e., arachidonic, 
eicosapentaenoic, and docosapentaenoic acids), increased risks were observed among men <62 
years (ORAA=1.05, 95%CI=1.02,1.08; OREPA=1.04, 95%CI=1.01,1.06; ORDPA=1.05, 
95%CI=1.02,1.08).  
Conclusion: Results from this study suggest that circulating ω-3 and ω-6 PUFAs may play a 
different role in the etiology of early- and late-onset prostate cancer.  
Keywords: Polyunsaturated fatty acids, prostate cancer, Mendelian randomization, polygenic 
risk score, linoleic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, 
docosapentaenoic acid, docosahexaenoic acid 
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INTRODUCTION 
 Prostate cancer is the most common cancer among Caucasian men worldwide (Torre et 
al, 2015).  Identifying modifiable prostate cancer risk factors could help to alleviate the burden 
of prostate cancer.  However, little is known about modifiable factors for this common cancer.  
 Several previous epidemiologic studies have examined the relation between 
polyunsaturated fatty acids (PUFAs) and prostate cancer risk (Zock & Katan, 1998; Carayol et 
al, 2010; Sakai et al, 2012; Alexander et al, 2015). Given the possible role that PUFAs may play 
in prostate carcinogenesis, with suggested anti-inflammatory effects for ω-3 PUFAs and 
inflammatory effects for ω-6 PUFAs (Berquin et al, 2011), an examination of these nutritional 
factors may be warranted. Specifically, metabolism of ω-6 PUFAs via the cyclooxygenase-2 
enzyme results in the production of inflammatory mediators including prostaglandin E2 that has 
been reported to affect prostate carcinogenesis (Sobolewski et al, 2010). Others include the 
lipoxygenase and cytochrome p450 pathways producing leukotrienes and 
hydroxyeicosatetraenoic acids, which have also been implicated in cancer development 
(Panigrahy et al, 2010; Wang & Dubois, 2010). On the contrary, products of ω-3 PUFA 
metabolism via these same biologic pathways have demonstrated anti-inflammatory properties 
(Chapkin et al, 2009). However, the association between PUFAs and prostate cancer risk is not 
supported by a recent meta-analysis summarizing prospective studies of long-chain ω-3 PUFA 
intake and prostate cancer incidence that reported null results for both self-reported dietary 
intakes and biomarker measures of PUFAs (Alexander et al, 2015). Observational studies of 
dietary factors and cancer risk are prone to biases, including confounding, selection bias, 
measurement error, and reverse causation. Measurement error is an important limitation for 
studies examining diet via food frequency questionnaires. While biomarker PUFA measurements 
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may provide an objective measure of intake, depending on the biomarker used (i.e., serum vs. red 
blood cell) the time period of exposure will vary (Arab, 2003), and thus an objective PUFA 
measurement may not represent the relevant etiologic time period. As a result, reverse causation 
in studies of prostate cancer and diet (regardless of whether diet was measured via food 
frequency questionnaire or biomarkers) may be of particular concern, given the slow growth of 
most prostate tumors and the prospect that men diagnosed with low risk (i.e., low volume and 
grade) disease may not be treated for several years in accord with current treatment guidelines. 
Given these potential limitations of observational studies the estimation of an unbiased 
(potentially causal) association may be difficult.  
 Mendelian randomization is based on the principle of random assortment of alleles at 
conception, and may identify causal risk factors for disease by utilizing a number of genetic 
variants (also known as the genetic instrument) as a proxy for an exposure. Previous genome-
wide association studies (GWAS) have identified several variants that together explain a large 
proportion of variation in PUFA levels, thus making them a potential candidate for Mendelian 
randomization analysis. 
We sought to identify potentially causal associations between genetically-predicted 
plasma PUFA levels and risk of developing prostate cancer using case-control data from a large 
consortium. In our Mendelian randomization analysis we examined the main ω-3 and ω-6 
PUFAs, including: (1) ω-6 PUFAs: linoleic acid (LA) and arachidonic acid (AA); and (2) ω-3 
PUFAs: α-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), 
and docosahexaenoic acid (DHA). 
 
MATERIALS AND METHODS 
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Study population 
We used the resources of the Prostate Cancer Association Group to Investigate Cancer 
Associated Alterations in the Genome (PRACTICAL), a large consortium of prostate cancer 
genetic association studies (Eeles et al, 2013). In our analysis, we excluded those individuals 
who were not of European ancestry (n=1,189) and all individuals from the Washington 
University Genetics Study (WUGS) case-only study (n=944) and the Prostate Cancer 
Mechanisms of Progression and Treatment (PrOMPT) study which had only 2 controls (n=168). 
The final analytic dataset consisted of 45,755 individuals (22,721 cases and 23,034 controls). 
 
Instrumental variables 
We used results from published GWAS conducted by the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) consortium examining plasma levels of ω-6 
(Guan et al, 2014) and ω-3 (Lemaitre et al, 2011) PUFAs in order to identify genetic variants 
associated with plasma PUFA levels. We also considered several variants identified from the 
metabolomics literature; however, many of these SNPs were either the same or in high linkage 
disequilibrium with those reported in the two CHARGE GWAS. Therefore, in total we identified 
23 SNPs associated with any PUFA trait from these two published GWAS. Of these, 14 were 
associated with the essential PUFAs [i.e., linoleic acid (LA), arachidonic acid (AA), alpha-
linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and 
docosahexaenoic acid (DHA)]. Finally, nine of these 14 SNPs were independent (r2 < 0.1), and 
thus were used in the genetic instrument for the Mendelian randomization analyses. Please refer 
to Supplement Figure 1 for a summary of SNP selection.  
For each variant selected, the allele that was associated with increased levels of plasma 
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PUFAs was considered the effect allele, and the summary statistics for these effect alleles were 
obtained from published PUFA GWAS (Lemaitre et al, 2011; Guan et al, 2014). Two of these 
selected variants (rs174547 and rs16966952) were associated with multiple PUFAs and, thus, 
were not exclusive to any particular genetic instrument.  
 
Genotyping and Imputation 
The PRACTICAL study samples were genotyped using a custom Illumina Infinium array 
(iCOGS) as part of the Collaborative Oncological Gene-environment Study (COGS), including 
more than 85,000 prostate cancer-related single nucleotide polymorphisms (SNPs) selected from 
four previous GWAS (UKGPCS, CGEMS, BPC3, and CAPS), fine mapping of known prostate 
cancer susceptibility regions at the time of custom chip design, and from candidate gene studies 
examining important biologic pathways (including hormone metabolism, cell cycle, and DNA 
repair) (Eeles et al, 2013). Standard quality control protocols were followed by excluding 
individuals with genotyping call rates <95%, heterozygosity greater than or less than 4.89 
standard deviations from the ethnicity-specific mean, duplicates, and relative pairs (Eeles et al, 
2013; Al Olama et al, 2014). SNPs with call rates <95% were excluded, as well as those 
deviating from Hardy-Weinberg Equilibrium in the controls at p value <1x10-7 (Eeles et al, 
2013; Al Olama et al, 2014). Of the nine SNPs associated with PUFAs included in our analysis, 
three were directly genotyped (rs780094, rs2236212, and rs174538) and six were imputed 
(rs3734398, rs3798713, rs1074011, rs174547, rs2727270, and rs1696695) with high quality (r2 > 
0.76).  SNPs were imputed in two stages; first using SHAPEIT (http://www/shapeit.fr/) by 
chromosome and chunk, and then data was phased with the haplotypes from 1000 Genomes 
Phase 3 (March 2012 release) which were then used for imputation using IMPUTE.V2 
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(https://mathgen.stats.ok.ac.uk/impute/impute_v2.html) (Eeles et al, 2013; Al Olama et al, 
2014).  
 
Weighted-polygenic risk scores (wPRSs) 
For analyses using individual-level data, an externally weighted-polygenic risk score 
(wPRS) was constructed for each PUFA separately using the SNPs associated with that fatty 
acid. Allele dosage was used for imputed SNPs. Using this information PUFA-specific wPRSs 
were constructed per individual where effect alleles were weighted according to their published 
associations from PUFA GWAS (Lemaitre et al, 2011; Guan et al, 2014), as follows: 
∑ 𝛽𝑖 ∗ 𝑆𝑁𝑃𝑖     ,
𝑛
𝑖=1
 
where SNPi represents the effect allele dosage and βi represents the increase in PUFA levels (as a 
percentage of total plasma fatty acids) for that specific variant, summed across each of the n 
variants used in the PUFA-specific wPRSs. Thus, the wPRS represents an increase in PUFA 
levels measured as percentage of total plasma fatty acids. The GWAS summary statistics for the 
association between each variant and PUFA trait are listed in Table 1. The theoretical maximum 
value for each PUFA-specific wPRS was 5.53, 3.78, 0.03, 0.24, 0.26, 0.23, for LA, AA, ALA, 
EPA, DPA, and DHA, respectively. The theoretical maximum value for each PUFA-specific 
wPRS per individual was calculated by taking the sum of the product of the GWAS effect allele 
summary estimate and the maximum number of effect alleles per SNP included in each PUFA-
specific instrument [e.g., maximum wPRS for AA = (1.691*2) + (0.199*2) = 3.78]. 
 
Statistical analyses 
 Unconditional logistic regression was used to estimate associations between genetically-
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predicted PUFA levels (wPRSs) and risk of prostate cancer per one standard deviation increase 
in predicted fatty acid levels. All models were adjusted for age, eight principal components for 
European ancestry, and PRACTICAL study site. We further assessed the relation between wPRS 
and prostate cancer risk using restricted cubic splines for those polygenic risk scores including 
more than one variant (LA, AA, EPA, DPA). Supplement Figures 2-5 display the shape of the 
dose-response between the wPRS and log-odds of prostate cancer from restricted cubic spline 
models suggesting non-linearity (Desquilbet & Mariotti, 2010).  
We also conducted stratified analyses to explore the relation between PUFAs and prostate 
cancer risk among subgroups, including smoking status (ever vs. never smokers), median age at 
diagnosis (<62 vs. ≥62 years), disease status (advanced vs. non-advanced prostate cancer), and 
method of detection (screen- vs. clinically-detected prostate cancer). Polytomous regression was 
used to estimate adjusted stratum-specific ORs and 95% CIs for the associations between PUFA-
specific wPRSs and disease status and method of prostate cancer detection. Statistically 
significant differences between strata of each potential effect measure modifier were assessed 
using the likelihood ratio test for the multiplicative interaction term (for smoking status and age 
at diagnosis), and using the test for homogeneity (for disease status and method of detection).  
Advanced prostate cancer included those cases with either Gleason score ≥8, died from prostate 
cancer, had metastatic disease, or prostate-specific antigen levels >100 ng/ml at diagnosis. We 
also compared the results for the associations between the PUFA-specific wPRS and prostate 
cancer from the pooled analysis using individual level data to the summary associations derived 
from meta-analyses of each PRACTICAL study (Supplement Figures 6-11). Analyses were 
conducted using SAS version 9.4 (Cary, NC), and STATA version 12.1 (College Station, TX). 
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Sensitivity analyses 
Several sensitivity analyses were conducted to assess the robustness of our results. First, 
we assessed whether the PUFA-specific wPRSs were associated with prostate cancer risk factors, 
namely age, body mass index, prostate specific antigen levels, smoking, alcohol intake, family 
history of prostate cancer, history of benign prostatic hyperplasia, history of prostatitis, and 
physical activity levels. Only age was significantly associated with most PUFA-specific wPRSs 
(with the exception of DHA), and physical activity was associated with the wPRSs for DPA and 
DHA. We compared models adjusting for different covariates; however our results did not 
change appreciably after controlling for age, eight principal components for European ancestry, 
PRACTICAL study site, or physical activity (Supplement Table 1). 
 Summary statistics from the previous PUFA GWAS (Lemaitre et al, 2011; Guan et al, 
2014) were used in tandem with the summary estimates from the PRACTICAL consortium to 
calculate the Mendelian randomization estimate using an inverse-variance weighted meta-
analysis approach (Burgess et al, 2013). We further standardized the Mendelian randomization 
ORs and 95% CIs to represent an increase in prostate cancer risk per one standard deviation 
increase for each PUFA-specific wPRS, thus representing a standard deviation increase in 
percentage of PUFA levels per total plasma fatty acids (Supplement Table 2). 
 
Assessing pleiotropy 
 Two data-driven approaches were used to formally assess the impact of genetic 
pleiotropy on our results using summary statistics. First, we assessed the impact of genetic 
pleiotropy and potentially invalid instruments using Egger regression (Bowden et al, 2015).  This 
approach assesses the validity of the genetic instrument and provides an estimate of the average 
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pleiotropic effect across genetic instruments used in the instrument (Supplement Table 2).    
Second, given several variants were included in the different PUFA-specific genetic 
instruments, we conducted a sensitivity analysis to account for this potential pleiotropy. This 
method also further evaluated the strength of the genetic instruments used in our analysis. Using 
a weighted-regression based approach, the association (Yg) between variant (g) and prostate 
cancer (Y) were regressed on the association (Xg) between that same variant (g) and the PUFA 
trait of interest (X), weighted by the inverse-variance (σYg-2) (Burgess et al, 2015; Burgess & 
Thompson, 2015). This approach accounts for the potential pleiotropy of variants used in each 
instrument on other PUFA traits. Results from this sensitivity analysis to account for potential 
pleiotropy and causal associations between PUFA subtypes are presented in Supplement Table 
3. 
 
RESULTS 
 In Table 1, we provide a list of PUFA-associated genetic variants and their GWAS-
reported results that were used to create the PUFA-specific wPRSs. Each PUFA-specific 
instrument explanatory variation ranged from 0.65% (for DHA) to approximately 33% (for AA). 
Due to the large size of the PRACTICAL consortium, the F-statistic for all the genetic variants 
was large (all F-statistics were >10) indicating a strong genetic instrument for the PUFA 
exposures of interest (Stock et al, 2002). 
 The associations between one standard deviation increase wPRSs with prostate cancer 
risk for the majority of PUFA-specific wPRSs were null (Table 2). When stratified by age, 
modest increases in prostate cancer risk were observed for AA (OR=1.05, 95% CI=1.02, 1.08), 
EPA (OR=1.04, 95% CI=1.01, 1.06), and DPA (OR=1.05, 95% CI=1.02, 1.08) among men less 
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than 62 years of age. Whereas a modest risk reduction was observed for LA (OR=0.95, 95% 
CI=0.92, 0.98), and ALA (OR=0.96, 95% CI=0.93, 0.98) among this same age group. No 
differences were observed when stratified by smoking status (ever vs. never smokers), disease 
status (advanced vs. non-advanced prostate cancer), or method of detection (screen-detected vs. 
clinically-detected prostate cancer). When modeled using the restricted cubic splines, the 
associations between the wPRS and prostate cancer risk were also null (data not shown). The 
pooled results for the association between PUFA-specific wPRSs and prostate cancer risk were 
nearly identical to the summary estimate derived from fixed- and random-effects meta-analyses 
of the wPRSs and prostate cancer risk across studies included in the PRACTICAL consortium 
(Supplement Figures 6-11). Furthermore, our results did not change after adjusting for different 
covariates, including age and physical activity which were found to be associated with the 
PUFA-specific wPRSs (Supplement Table 1). We also conducted a Mendelian randomization 
analysis via the two-sample method using summary statistics scaled per one standard deviation 
unit increase (Supplement Table 2), and the results were nearly identical to those obtained from 
the individual-level analysis using wPRSs.  
 The impact of pleiotropic variants on the Mendelian randomization estimate was assessed 
using two different approaches, Egger regression and a weighted-regression based method. With 
the exception of the wPRS for DPA (β0=0.01304, p<0.0001), we did not observe any statistically 
significant intercepts as an indication of potential pleiotropic effects and an invalid instrument 
(Supplement Table 2). We also assessed the impact of pleiotropic variants on other PUFA traits 
via the weighted-regression based approach and, in general, observed little difference between 
the unadjusted models and models adjusted for potential pleiotropic effects on other PUFA traits 
(Supplement Table 3). A 12% risk reduction (95% CI=0.60, 1.29) for AA, and a 10% increased 
15 
 
risk (95% CI=0.88, 1.36) for ALA were indicated after adjusting for the potential pleiotropic 
effects of the instrument on other PUFA traits; however, the confidence intervals were imprecise.   
  
DISCUSSION 
 We examined the association between genetically-predicted plasma PUFA levels (via 
construction of PUFA-specific wPRSs) using individual-level data and summary statistics for 
PUFAs in relation to prostate cancer risk. Our findings suggest no overall association between 
plasma PUFA levels and risk of developing prostate cancer. However, a potential interaction 
with age (<62 vs. ≥62 years of age) was observed. 
 Meta-analysis results from previous studies of Caucasian populations reported a null 
association for studies examining self-reported dietary intakes of long-chain ω-3 PUFAs 
(summary RR=1.00, 95% CI=0.93, 1.09), and a modest, but not statistically significant, 
increased risk for studies examining biomarkers (summary RR=1.07; 95% CI=0.94, 1.20) 
(Alexander et al, 2015). The meta-analysis also suggested prostate cancer risk reductions from 
studies that examined DPA intake via self-report (summary RR=0.92; 95% CI=0.71, 1.19) and 
biomarkers (summary RR=0.85, 95% CI=0.72, 0.99). Results from another meta-analysis of 
prospective studies reported null associations with high intake of ALA in relation to prostate 
cancer risk (Carayol et al, 2010). Although our results for the overall null association were 
consistent with findings from previous studies as summarized in the two meta-analyses described 
above, we found that the association between PUFAs and prostate cancer risk may be modified 
by age at onset. Stratification by age at onset may have revealed the cumulative effect of PUFAs 
on prostate cancer risk. Given germline genetic variation will not vary over time, and if we 
assume that the wPRS is representative of a cumulative lifetime exposure to PUFAs, then it is 
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possible that a higher magnitude of the effect would have been revealed for older men (e.g., 
increased risk for ω-6 would have been stronger and reduced risk would have been lower for ω-3 
PUFAs among older men). However, our results indicate modest increases in risks for LA and 
modest reduced risks for long-chain ω-3 PUFAs (EPA, DPA, and DHA) among older men (≥62 
years of age) relative to younger men (<62 years). It is also possible that prostate cancer cases 
diagnosed at less than 62 years of age could reflect a more aggressive form of disease. However, 
when we considered stratification by disease severity the increased risks were not observed. 
Thus, additional research may be needed to disentangle the effects of screening and the potential 
for outcome misclassification of aggressive versus indolent prostate cancer cases. For ω-6 
PUFAs, a systematic review reported no strong positive association for AA (either dietary or 
biomarker) in relation to prostate cancer risk (Sakai et al, 2012), nor was an association observed 
in a meta-analysis of dietary LA intake and prostate cancer risk (Zock & Katan, 1998). 
 Although our study was sufficiently large to detect associations between PUFAs and 
prostate cancer incidence, several limitations remain. First, Mendelian randomization assumes 
the genetic instrument is: (1) associated with the exposure; (2) not associated with any 
confounders of the exposure-outcome association; and (3) independent of the outcome given the 
exposure and confounders (i.e., the genetic instrument only affects the outcome via the exposure 
of interest) (Burgess et al, 2015; Burgess & Thompson, 2015). The validity of the Mendelian 
randomization estimate hinges on these assumptions. In our study, the F-statistics for all the 
genetic instruments were large (>10) indicating strong genetic instruments that are associated 
with the exposure. However, for many of the PUFA-specific instruments the percentage of 
variation explained was low (<3%), and future research investigations should identify additional 
variants to incorporate into the genetic instruments to further improve the instrument strength. 
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Furthermore, the PUFA-specific genetic instruments were not associated with potential 
confounders, with the exception of physical activity for DPA and DHA. However, adjustment for 
physical activity did not alter our conclusions, thus providing additional evidence that the genetic 
instruments utilized in this analysis are independent of confounders. The only potential concern 
regarding the validity of the genetic instrument is the possibility of unknown pleiotropic effects, 
which would violate the aforementioned third assumption. Even though this analysis used 
several common GWAS-identified variants in the PRS, there are likely additional rare variants 
that were not included in this analysis and have yet to be discovered. However, even with the 
inclusion of potential rare variants, the percent variation explained by the genetic instrument may 
not be vastly improved unless these rare variants are found to have large effects. Further 
replication by others is required to elucidate the true associations for other PUFAs, including the 
long-chain ω-3 PUFAs for which anti-inflammatory action has been suggested by laboratory 
studies (Berquin et al, 2011). Although we examined stratification by disease status, the 
possibility for misclassification of aggressive versus low-risk prostate cancer cases remains. 
Future advancements in prostate cancer screening, via serum (i.e., prostate health index or 
Kallikrein protein levels) or urinary (i.e., PCA3 or TMPRSS2-ERG fusion) markers (Cuzick et al, 
2014), may help to better separate aggressive prostate cancer from low-risk indolent cases, which 
may help to potentially reveal the benefits of long-chain ω-3 PUFAs among truly aggressive 
prostate cancers.   
Our analysis has several strengths. First, we conducted analyses using individual level 
data, which allowed us to control for potential confounders of the association between the wPRS 
and prostate cancer risk, including principal components for European ancestry. The individual-
level analysis also allowed us to examine effect measure modification by conducting stratified 
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analyses. Second, we conducted our analysis using a large sample of data from the PRACTICAL 
consortium. Furthermore, we utilized available summary statistics data from this large 
PRACTICAL consortium and effect estimates from previous PUFA GWAS to conduct a two-
sample Mendelian randomization analysis. Given large sample sizes of these studies and the use 
of independent variants in each genetic instrument, the Mendelian randomization estimate from 
the two-sample approach using summary statistics will be equivalent to the Mendelian 
randomization estimate from a one-sample approach (via two-stage least-squares regression) 
with available genetic and biomarker information (Haycock et al, 2016). Although, we did not 
observe any substantial pleiotropic effects when we conducted the weighted-regression based 
method (Burgess et al, 2015; Burgess & Thompson, 2015) nor via Egger regression (Bowden et 
al, 2015), we are unable to completely rule out the impact of unknown pleiotropic effects which 
could reduce the validity of the Mendelian randomization estimate (in particular for DPA, for 
which the Egger’s p value was statistically significant). Lastly, the proportion of variation 
explained by the SNPs included in the genetic instrument for several PUFAs (AA, LA, and 
DPA) was relatively high compared to other Mendelian randomization studies examining other 
traits (Ehret et al, 2011; Ahmad et al, 2015). Thus, the Mendelian randomization association may 
reflect the true null association, but requires confirmation by others, using instruments that 
include additional variants and explain an even higher percentage of variation in fatty acid levels 
(especially for those PUFAs for which the percentage of variation explained was low). 
In conclusion, using data from a large consortium, we report an overall null association 
between PUFAs (both ω-3 and ω-6) and prostate cancer risk. Specifically, we report no 
association for AA in relation to prostate cancer incidence, for which the strength of the 
instrument and proportion of variation explained, was high. However, increased risks were 
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indicated for men less than 62 years of age for genetically-predicted increases in long-chain ω-6 
(AA). Similar increases were observed for long-chain ω-3 PUFAs (EPA and DPA) among this 
age group, which is contrary to what would be expected, given the hypothesized anti-
inflammatory action of long-chain ω-3 PUFAs. Future investigations into these different 
associations by age at onset could help to elucidate the roles of PUFAs in the etiology of prostate 
cancer. 
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